Washington, D.C. (JULY 31, 2025) – Saul Ewing LLP congratulates firm client Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) on the successful completion of its previously announced acquisition of Sage Therapeutics, Inc. (Nasdaq: SAGE). This strategic acquisition strengthens Supernus’ leading presence in neuropsychiatric conditions through the addition of the innovative commercial product ZURZUVAE® and a novel CNS discovery platform—positioning the company for accelerated mid- to long-term revenue and cash flow growth, while further diversifying its revenue base.
Our team of attorneys, led by Partner Mark Gruhin, is proud to have supported this important milestone and looks forward to Supernus’ continued success.
Read Supernus' press release here.
About Saul Ewing
Saul Ewing is a full-service, national law firm with more than 400 attorneys and a team of top-notch business professionals, all working together to deliver practical, proactive advice and excellent client service. Our diversity of thought, focus on innovation, cross-serving practices, and culture of coaching create a collegial and supportive environment that inspires us to deliver inspired solutions. This is The Saul Approach.
